What DyAnsys does

DyAnsys is a privately held medical device company founded in 2015 and headquartered in Silicon Valley, California, that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system (ANS) monitoring equipment. The company focuses on the under-served area of ANS measurement and non-narcotic pain and addiction therapy, serving healthcare providers across multiple specialties including pain management, addiction treatment, endocrinology/diabetology, anesthesiology, and cardiology.

The company's product portfolio rests on two underlying technology platforms: (i) percutaneous auricular neurostimulation — including percutaneous electrical nerve stimulation (PENS) and percutaneous electrical nerve field stimulation (PNFS) — which delivers low-level electrical pulses via needles placed in ear nerve endings to trigger endorphin release, embodied in the Primary Relief, Drug Relief, and First Relief devices; and (ii) ANS diagnostics via the ANSiscope, which measures heart rate variability (HRV) from ECG-derived R-R intervals to quantify parasympathetic/sympathetic balance. Diagnostic ECG hardware is sold under the ECScope brand. Multiple FDA clearances across distinct indications — opioid withdrawal (2018), diabetic peripheral neuropathy (2022), and post-operative pain following C-section and cardiac surgery (2022) — and a proprietary HRV algorithm validated on over 100,000 patients underwrite the IP base, with First Relief and ANSiscope patented in the USA and other jurisdictions.

DyAnsys operates a hybrid go-to-market: disposable single-use devices are sold primarily through an authorized global distributor network (with European distribution channeled through wholly-owned DyAnsys Europe SARL in Switzerland), alongside direct sales to hospitals, surgical centers, pain clinics, and addiction treatment facilities. Manufacturing is conducted through DyAnsys India Private Ltd, a wholly-owned subsidiary. Pricing is quote-based and not publicly disclosed, and revenue streams are concentrated in hardware sales of regulated medical devices. No revenue figures, funding rounds, or headcount are disclosed; the company appears to be founder/management-owned under CEO Srini Nageshwar.

Name

DyAnsys

Legal name

DyAnsys Inc.

Website

https://dyansys.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

DyAnsys is a privately held medical device company that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system monitoring equipment to healthcare providers across pain management, addiction treatment, diabetic care, anesthesiology, and cardiology specialties.

Ownership category

akta.pro rank

Product category

Medical Devices (Neuromodulation and Diagnostics)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industries

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM), Autonomic Disorders (Dysautonomia) (HLAKAIAN)

Keywords

• Neurostimulation medical devices
• Pain management devices
• Autonomic nervous system monitoring
• FDA-cleared neuromodulation
• Electrocardiogram equipment

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: DyAnsys generates revenue from the sale of FDA-cleared neurostimulation medical devices including Primary Relief, First Relief, and Drug Relief. Devices are single-use/disposable and sold in packages (e.g., Drug Relief 5 per box). Sold through distributors and directly to healthcare providers.
2. ECG Equipment Sales: DyAnsys markets a line of electrocardiogram (ECG) machines designed for doctor's offices and hospital settings, sold as medical diagnostic equipment.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

DyAnsys develops and sells FDA-cleared auricular neurostimulation medical devices that deliver low-level electrical pulses through needles placed in the ear to stimulate nerve endings and trigger endorphin release for non-narcotic pain management and opioid withdrawal aid. Its portfolio includes Primary Relief® (post-operative pain), Drug Relief® (opioid withdrawal), First Relief® (diabetic peripheral neuropathy), the ANSiscope® autonomic nervous system monitor, and ECScope 100™ electrocardiogram equipment for clinical settings.

Product overview

DyAnsys provides a portfolio of advanced medical diagnostic and monitoring systems, centered on autonomic nervous system (ANS) measurement and neurostimulation therapy. The product lineup consists of five core offerings: ANSiscope®, a diagnostic HRV-based ANS monitoring device used for measuring autonomic dysfunction; ECScope 100™, an electrocardiogram machine for clinical settings; and three percutaneous electrical neurostimulation (PENS/PNFS) devices — Primary Relief® (for post-operative pain including cardiac surgery and C-section), First Relief® (for diabetic neuropathic pain), and Drug Relief® (for opioid withdrawal aid). All three neurostimulation devices are wearable, ear-worn devices that deliver electrical pulses through needles inserted at auricular nerve endings. The company also provides a Testing System used by distributors to verify proper functioning of neurostimulator devices.

Differentiator

Problem solved

Functional benefit

Brands

• First Relief: FDA-cleared percutaneous electrical neurostimulation (PENS) device for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy, cleared for multiple treatments up to 56 days
• Primary Relief
• Drug Relief
• ANSiscope
• ECScope 100

Products and services

• Primary Relief® A percutaneous electrical neurostimulation (PENS) device worn behind the ear that delivers continuous low-level electrical pulses through ear nerve endings for up to 72 hours, providing symptomatic relief of post-operative pain following cardiac surgery and C-section delivery for hospitals and surgical centers.
• Drug Relief® A percutaneous electrical nerve field stimulator (PNFS) placed behind the ear with tiny needles inserted in ear nerve endings, sending continuous electrical pulses over 120 hours to reduce symptoms of opioid withdrawal during detoxification for addiction treatment centers and physicians managing opioid dependency.
• First Relief® A percutaneous electrical neurostimulation (PENS) device applied behind the ear that delivers continuous pulses of low-level electrical current, FDA-cleared for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy for pain management physicians and diabetologists.
• ANSiscope® An autonomic nervous system (ANS) monitoring device that measures parasympathetic and sympathetic system activity with every heartbeat through heart rate variability (HRV) analysis from ECG-derived R-R intervals, providing specific measurements of autonomic dysfunction and sympathovagal balance for diabetologists, endocrinologists, and clinical researchers.
• ECScope 100™ A line of electrocardiogram (ECG) machines designed for doctor's office and hospital settings, featuring high sensitivity without excessive filtering techniques that could mask subtle cardiac problems, marketed as an affordable diagnostic option for primary care and cardiology practices.

Quantifiable outcome

• Mean fentanyl dosage as rescue analgesic in post-operative period was only one-third of control group in clinical trial
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• NeuroMetrix: NeuroMetrix is a small-cap medical device company that markets wearable neurostimulation devices (e.g., Quell for chronic pain, DPNCheck for diabetic peripheral neuropathy). It is a direct peer to DyAnsys in percutaneous/wearable electrical neurostimulation for diabetic neuropathy and chronic pain, targeting overlapping HCP and patient populations.
• ElectroCore: ElectroCore makes non-invasive vagus nerve stimulation (nVNS) devices, including gammaCore for headache/migraine and other indications. It is a direct peer to DyAnsys in non-pharmacologic, device-based neuromodulation for pain and neurological indications, using electrical stimulation through cutaneous/auricular access points.
• SPR Therapeutics: SPR Therapeutics markets SPRINT PNS, a minimally invasive peripheral nerve stimulation system for acute and chronic pain. It is a direct peer to DyAnsys in percutaneous, short-duration peripheral neurostimulation for post-operative and chronic pain management.

Broad incumbents

• Medtronic: Medtronic is a global medical device leader with broad neuromodulation franchises including spinal cord stimulators, deep brain stimulators, and targeted drug delivery for chronic pain. It is a broad incumbent competing with DyAnsys across multiple pain and addiction indications with much larger commercial scale.
• Boston Scientific: Boston Scientific operates a sizable Neuromodulation division (spinal cord stimulators, WaveWriter, Vertis, etc.). It is a broad incumbent in the same clinical pain categories where DyAnsys competes, though with implant-based rather than percutaneous/wearable systems.
• Abbott: Abbott (formerly St. Jude Medical) sells Proclaim DRG and other neuromodulation systems for chronic pain. It is a broad incumbent competing for hospital and pain clinic budgets allocated to neurostimulation-based pain therapy.

Emerging players

• Innovative Health Solutions: IHS (now part of Spark Biomedical) markets the NSSysta/BRIDGE auricular neurostimulation device and has been used in opioid withdrawal and pain management protocols. It is an emerging player targeting the same auricular/PNFS niche as DyAnsys' Drug Relief.
• Cefaly: Cefaly Technology makes an external trigeminal nerve stimulation device (Cefaly device) for migraine prevention and acute treatment. It is an emerging player in non-invasive peripheral neurostimulation for pain with overlapping neurology referral channels.
• Axonics: Axonics Modulation Technologies develops and markets sacral neuromodulation systems (snm systems) for overactive bladder, urinary retention, and fecal incontinence. It is an emerging player in implant-based neurostimulation that competes for HCP relationships and payer formulary attention adjacent to DyAnsys' area.

Others

• Masimo: Masimo is a patient monitoring and pulse oximetry company whose signal extraction technology underpins many ECG and HRV-based monitors. It is an adjacent/oth ers peer to DyAnsys' ANSiscope HRV-based autonomic monitoring franchise, supplying enabling technology and competing indirectly in clinical monitoring budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/DyAnsysOnline
• Facebookfacebook.com/pages/DyAnsys/120038391428623?ref=tn_tnmn
• Xx.com/DyAnsys
• LinkedInlinkedin.com/company/dyansys-india-p-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DyAnsys